NU SKIN ENTERPRISES, INC.

Listed Company

NUSCIK 0001021561NYSEAcceleratedWholesale-Drugs, Proprietaries & Druggists' SundriesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$1.49B

Net Income

$160.20M

Total Assets

$1.41B

Equity

$805.24M

Shares Out

48.55M

Op. Cash Flow

$80.29M

NUS$5.23−36.72% · past yearDBEQ Basic

Daily closing prices

Business

Nu Skin Enterprises, Inc. develops and distributes premium beauty and wellness products through direct selling in nearly 50 markets worldwide. The company offers skincare, cosmetics, nutritional supplements, and connected beauty devices under brands including Nu Skin, Pharmanex, ageLOC, and Nutricentials. Nu Skin operates a person-to-person and digital-enabled sales channel with independent Brand Affiliates and consumers, supplemented by a Rhyz strategic investment arm that includes manufacturing, ingredient technology, packaging, and other consumer companies.

Summary from 10-K filed 2026-02-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	1,485	1,732	1,969	2,226	2,696
Cost of sales	454	550	612	631	675
Gross profit	1,031	1,182	1,357	1,595	2,020
Selling expenses	508	652	742	880	1,080
General and administrative expenses	432	479	547	556	654
Restructuring and impairment expenses	25	202	20	48	52
Total operating expenses	966	1,333	1,309	1,484	1,786
Operating income (loss)	66	−152	48	111	234
Interest expense	14	26	26	13	—
Gain on sale	176	0	0	—	—
Other income (expense), net	−32	3	4	−8	−2
Income (loss) before provision for income taxes	196	−175	27	89	232
Provision (benefit) for income taxes	36	−28	18	−16	85
Net income (loss)	160	−147	9	105	147
Basic (in dollars per share)	3.25	−2.95	0.17	2.1	2.93
Diluted (in dollars per share)	3.18	−2.95	0.17	2.07	2.86
Basic (in shares)	49	50	50	50	50
Diluted (in shares)	50	50	50	51	51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	239	187	256	265	340
Current investments	1	11	12	14	15
Accounts receivable, net	40	51	59	47	41
Inventories, net	179	190	280	346	400
Prepaid expenses and other	90	73	81	88	77
Current assets held for sale	0	27	14	—	—
Total current assets	548	539	702	760	873
Property and equipment, net	377	380	433	445	454
Operating lease right-of-use assets	74	73	90	99	121
Goodwill	84	84	218	206	206
Other intangible assets, net	43	74	95	67	77
Other assets	280	298	248	244	175
Long-term assets held for sale	0	22	23	—	—
Total assets	1,405	1,469	1,809	1,821	1,906
Accounts payable	26	35	43	54	50
Accrued expenses	218	218	254	280	372
Current portion of long-term debt	20	30	25	25	108
Current liabilities held for sale	0	14	7	—	—
Total current liabilities	264	297	329	359	530
Operating lease liabilities	58	58	71	77	89
Long-term debt	204	364	478	377	269
Other liabilities	75	97	107	110	106
Long-term liabilities held for sale	0	1	2	—	—
Total liabilities	600	817	987	924	994
Commitments and contingencies (Notes 8 and 17)	—	—	—	—	—
Class A common stock - 500 million shares authorized, $0.001 par value, 90.6 million shares issued	91,000	91,000	91,000	91,000	91,000
Additional paid-in capital	636	628	622	613	602
Treasury stock, at cost - 42.4 million and 40.8 million shares	−1,575	−1,564	−1,570	−1,569	−1,527
Accumulated other comprehensive loss	−116	−125	−100	−87	−74
Retained earnings	1,860	1,712	1,870	1,939	1,912
Total stockholders' equity	805	651	822	897	913
Total liabilities and stockholders' equity	1,405	1,469	1,809	1,821	1,906

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	52	70	71	73	76
Non-cash lease expense	26	27	33	45	49
Stock-based compensation	24	15	16	12	23
Inventory write-down	4	48	88	43	31
Foreign currency losses	6	2	1	8	7
(Gain) loss on disposal of assets	160,000	−84,000	780,000	33,000	13
Impairment of fixed assets, goodwill and other intangibles	25	181	0	10	32
Unrealized losses on equity investments	28	0	0	—	—
Deferred taxes	20,000	−55	−18	−52	6
Accounts receivable, net	10	−8	−23	−11	20
Inventories, net	12	30	−13	−3	−127
Prepaid expenses and other	−20	579,000	6	3	15
Other assets	−9	−1	45,000	3	−20
Accounts payable	−9	−7	−10	9	−13
Accrued expenses	−54	−28	−38	−121	−105
Other liabilities	858,000	−16	−4	−16	4
Net cash provided by operating activities	80	112	119	108	142
Purchases of property and equipment	−34	−42	−58	−59	−69
Proceeds on investment sales	10	18	18	6	15
Purchases of investments	0	−15	−17	−14	−16
Acquisitions (net of cash acquired)	0	0	−77	0	−19
Proceeds from sale of business, net	194	0	0	—	—
Other, net	1	0	0	—	—
Net cash provided by (used in) investing activities	171	−38	−135	−67	−89
Exercise of employee stock options and taxes paid related to the net shares settlement of stock awards	−2	−2	5	27	14
Payment of cash dividends	−12	−12	−78	−77	−76
Repurchase of shares of common stock	−20	0	−13	−70	−80
Finance lease principal payments	−2	−3	−3	−2	−2
Contingent consideration payments	0	−6	0	0	—
Payments on debt	−225	−125	−10	−433	−115
Proceeds from debt	55	15	110	460	155
Other, net	4	0	0	—	—
Net cash (used in) provided by financing activities	−202	−133	11	−100	−105
Effect of exchange rate changes on cash	3	−10	−4	−16	−11
Net increase (decrease) in cash and cash equivalents	52	−69	−9	−75	−63

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is NU SKIN ENTERPRISES, INC.'s CIK number?

NU SKIN ENTERPRISES, INC.'s SEC CIK number is 0001021561 (1021561). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find NU SKIN ENTERPRISES, INC.'s SEC filings?

All of NU SKIN ENTERPRISES, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did NU SKIN ENTERPRISES, INC. last report earnings?

NU SKIN ENTERPRISES, INC. (NUS) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001140361-26-019586). This is NU SKIN ENTERPRISES, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is NU SKIN ENTERPRISES, INC.'s most recent earnings 8-K?

NU SKIN ENTERPRISES, INC.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001140361-26-019586. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View NU SKIN ENTERPRISES, INC.'s latest earnings 8-K →
Look up any company's CIK number →